Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [3406]
News [7771]
Articles [63]
Editorials [9]
Conferences [207]
elearning [49]
CDK 4/6 inhibitors for metastatic breast cancer
Dr Giuseppe Curigliano, Dr Carmen Criscitiello, Dr Ghadeer Shubassi, Prof...
CDK 4/6 inhibitors for metastatic breast cancer ( Dr Giuseppe Curigliano, Dr Carmen Criscitiello, Dr Ghadeer Shubassi, Prof Pierfranco Conte )
20 Mar 2017
Evaluating efficacy of denosumab compared with zoledronic acid in symptomatic...
Dr Noopar Raje - Massachusetts General Hospital, Boston, USA
Evaluating efficacy of denosumab compared with zoledronic acid in symptomatic myeloma ( Dr Noopar Raje - Massachusetts General Hospital, Boston, USA )
4 Mar 2017
Update on CASTOR trial: Daratumumab, bortezomib, and dexamethasone for relapsed...
Dr Suzanne Lentzsch - Columbia University, New York, USA
Update on CASTOR trial: Daratumumab, bortezomib, and dexamethasone for relapsed or refractory myeloma ( Dr Suzanne Lentzsch - Columbia University, New York, USA )
3 Mar 2017
Impact of recurrent myeloma alterations on drug response
Dr Muntasir Mamun Majumder - University of Helsinki, Helsinki, Finland
Impact of recurrent myeloma alterations on drug response ( Dr Muntasir Mamun Majumder - University of Helsinki, Helsinki, Finland )
3 Mar 2017
Is precision myeloma medicine more hype than reality?
Dr Suzanne Lentzsch - Columbia University, New York, USA
Is precision myeloma medicine more hype than reality? ( Dr Suzanne Lentzsch - Columbia University, New York, USA )
3 Mar 2017
Denosumab vs zoledronic acid for bone disease in newly diagnosed multiple...
Prof Evangelos Terpos - University of Athens School of Medicine, Athens, Greece
Denosumab vs zoledronic acid for bone disease in newly diagnosed multiple myeloma ( Prof Evangelos Terpos - University of Athens School of Medicine, Athens, Greece )
3 Mar 2017
Promising myeloma agents in phase II trials
Dr Ruben Niesvizky - New York Presbyterian Hospital-Weill Cornell Medical...
Promising myeloma agents in phase II trials ( Dr Ruben Niesvizky - New York Presbyterian Hospital-Weill Cornell Medical Center, New York, USA )
2 Mar 2017
Post autologous transplant therapies in high risk multiple myeloma: StaMINA...
Dr Amrita Krishnan - City of Hope Cancer Center, Duarte, USA
Post autologous transplant therapies in high risk multiple myeloma: StaMINA trial update ( Dr Amrita Krishnan - City of Hope Cancer Center, Duarte, USA )
2 Mar 2017
Pomalidomide and low-dose dexamethasone for relapsed or refractory multiple...
Dr David Siegel - John Theurer Cancer Center, Hackensack, USA
Pomalidomide and low-dose dexamethasone for relapsed or refractory multiple myeloma ( Dr David Siegel - John Theurer Cancer Center, Hackensack, USA )
2 Mar 2017
Teaming up with competitors in HARMONY
Tayyab Salimullah - Novartis Oncology, Basel, Switzerland
Teaming up with competitors in HARMONY ( Tayyab Salimullah - Novartis Oncology, Basel, Switzerland )
13 Feb 2017
Data modelling in the HARMONY project
Prof Giovanni Martinelli - University of Bologna, Bologna, Italy
Data modelling in the HARMONY project ( Prof Giovanni Martinelli - University of Bologna, Bologna, Italy )
2 Feb 2017
Interlinked research into haematological malignancies
Prof Lars Bullinger - Ulm University, Ulm, Germany
Interlinked research into haematological malignancies ( Prof Lars Bullinger - Ulm University, Ulm, Germany )
2 Feb 2017

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation